What insurance policy changes affect code D71?

There are 4 tracked policy changes affecting code D71, including updates from Blue Cross & Blue Shield of Mississippi, Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D71?

Payers that have issued tracked updates for code D71 include: Blue Cross & Blue Shield of Mississippi, Independence Blue Cross, Aetna.

How do I get notified when code D71 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D71. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D71?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

D71 Insurance Policy Changes

code D71 is referenced in 4 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi, Independence Blue Cross, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D71 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Complete Blood Count, Hemoglobin, and Hematocrit
A hemoglobin (Hgb), hematocrit (Hct), red blood cell count (RBC), or complete blood count (CBC) may be considered medically necessary for listed indications, including bone marrow dysfunction, red blood cell disorders, polycythemia, and other listed conditions. A CBC may be considered medically necessary for listed white blood count and platelet indications and other listed conditions, and these tests are considered not medically necessary for all other indications. On 10/01/2026, the Code Reference section was updated to remove ICD-10 codes B88.0, D71, G35, R10.2, R76.8, and Z84.1 and to add ICD-10 codes including K6A.01, K6A.09, K6A.8, K74.0A, and K76.83.
Independence Blue Cross · Effective Oct 1, 2025Medium impact
08.00.13al, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross updated policy 08.00.13al to version 08.00.13ao, removing coverage for Functional disorders of polymorphonuclear neutrophils (D71) and broad Multiple sclerosis (G35), while adding coverage for the more specific diagnosis code Relapsing-remitting multiple sclerosis (G35.A). Billing teams must update diagnosis code logic to reflect these ICD-10 changes effective October 1, 2025.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)
Aetna considers autologous hematopoietic cell transplantation medically necessary for adults 18 to 69 years old with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure. This applies when active interstitial lung disease is present with a forced vital capacity or diffusing capacity of the lung for carbon monoxide below 70% of predicted, or when previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, if there are none, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic hematopoietic cell transplantation experimental, investigational, or unproven for conditions including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, myasthenia gravis, type I diabetes mellitus, age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera, and thrombotic thrombocytopenic purpura.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)
Aetna's Clinical Policy Bulletin 0606 covers hematopoietic cell transplantation for autoimmune diseases and other listed conditions. Aetna considers autologous transplant medically necessary for adults aged 18 to 69 with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure when either active interstitial lung disease with an FVC or DLCO below 70% of predicted is present, or previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, where none exist, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic transplant experimental, investigational or unproven for many autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, type 1 diabetes and myasthenia gravis, and for miscellaneous conditions such as age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera and thrombotic thrombocytopenic purpura.

Watch D71

Get one email when a payer policy names D71, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Complete Blood Count, Hemoglobin, and Hematocrit

08.00.13al, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)

What insurance policy changes affect code D71?

Which payers have updated policy for code D71?

How do I get notified when code D71 policy changes?

Why do payers change policies for code D71?